{
    "title": "Nervecentre - Encounter 5",
    "component": "RawClinicalNote",
    "props": {
        "encounterNumber": 5,
        "date": "2024-08-14",
        "visitType": "Outpatient",
        "provider": "Dr. R. Hall",
        "specialty": "Rheumatology",
        "rawText": "\n### **Nervecentre**\n\n**Module:** Laboratory Alerting & Medicines Safety\n**Event Type:** *Critical Medicine-Related LFT Alert \u2013 Methotrexate Patient*\n\n---\n\n## **1. Alert Event Summary**\n\n* **System Alert ID:** NC-LFT-20240814-003\n* **Patient:** Sarah Miller (MRN: SM43850603, DOB: 1981-06-03, 43F)\n* **Linked Encounter:**\n\n  * Visit Type: Outpatient \u2013 Rheumatology Review\n  * Date & Time: **2024-08-14 @ 14:32**\n  * Clinician: **Dr. R. Hall (Rheumatology Registrar)**\n* **Ordering Provider:** Dr. R. Hall\n* **Requesting Location:** Rheumatology Clinic \u2013 Room 5\n\n---\n\n## **2. Trigger Details**\n\n* **Trigger Rule:**\n\n  * **Rule 4.5 \u2013 ALT \u2265 3 \u00d7 ULN OR ALT \u2265 2 \u00d7 ULN in patients on hepatotoxic drugs (MTX).**\n\n* **Analyte Triggering Alert:**\n\n  * **ALT: 158 U/L** (ULN 40 U/L \u2192 **3.95 \u00d7 ULN**)\n\n* **Associated LFTs:**\n\n  * AST: 132 U/L (H)\n  * ALP: 118 U/L (N)\n  * Total Bilirubin: 17 \u03bcmol/L (N)\n  * Direct Bilirubin: 4 \u03bcmol/L (N)\n  * INR: 1.1 (N)\n  * Platelets: 238 \u00d7 10\u2079/L (N)\n\n* **Pattern of Injury:**\n\n  * **Hepatocellular**, ALT > AST > 3\u00d7 ULN, normal bilirubin\n\n* **Alert Level:** **Level 3 \u2013 *Critical hepatotoxicity (MTX patient)***\n\n* **Severity Banding:**\n\n  * MTX patient with ALT >3\u00d7 ULN \u2192 **\u201cImmediate clinical review required\u201d**\n\n* **Medication Linkage:**\n\n  * Methotrexate 15mg weekly (started ~12 weeks prior)\n  * Folic acid 5mg weekly\n\n---\n\n## **3. Distribution & Delivery Log**\n\n**Primary Recipients:**\n\n* Dr. R. Hall (Ordering clinician)\n* Rheumatology Consultant On-Call\n* GP (auto-copied for medicine safety review)\n\n**Secondary Recipients:**\n\n* Pharmacy / DMARD Safety Team (Queue: *DMARD-SAFETY-PRIORITY*)\n* Nervecentre Medicines Safety Dashboard\n\n**Delivery Channels:**\n\n* Nervecentre mobile push\n* Desktop inbox message\n* Email notification to Rheumatology duty mailbox (policy-mandated for Level 3 alerts)\n\n**Delivery Timeline:**\n\n1. **2024-08-14 14:33:10** \u2013 LFTs verified by lab\n2. **2024-08-14 14:33:16** \u2013 Rule 4.5 fired (ALT 158)\n3. **2024-08-14 14:33:20** \u2013 High-priority alert created\n4. **2024-08-14 14:33:25** \u2013 Push & desktop alerts sent to Rheumatology\n5. **2024-08-14 14:33:28** \u2013 Medicines Safety Dashboard updated (red flag)\n\nCurrent status: **Alert acknowledged by Dr. Hall at 14:41**\nEscalation aborted (acknowledged in time)\n\n---\n\n## **4. Acknowledgment & Escalation Logic**\n\n* **Acknowledgement Requirement:**\n\n  * Level 3 alerts require action **within 2 hours**.\n\n* **Acknowledgement Status:**\n\n  * **Acknowledged \u2013 Dr. Hall at 14:41**\n  * Comment: \u201cMTX held. Repeat LFTs in 48h. Arrange fibrosis screen & ultrasound.\u201d\n\n* **Escalation Path (not triggered):**\n\n  * Rheumatology Consultant (15 min delay)\n  * Duty Manager (if >2h unacknowledged)\n  * Pharmacy DMARD team (parallel escalation)\n\n---\n\n## **5. Linked Tasks (Automatic)**\n\n### **1. NC-TASK-20240814-MTX-HOLD**\n\n* **Title:** \u201cSuspend Methotrexate pending repeat LFTs\u201d\n* **Owner:** Dr. R. Hall\n* **Due:** Immediate\n* **Status:** **Completed (14:42)**\n* **Notes:** MTX paused; patient notified.\n\n---\n\n### **2. NC-TASK-20240814-LFT-REPEAT48H**\n\n* **Title:** \u201cRepeat LFT panel in 48 hours (MTX hepatotoxicity)\u201d\n* **Owner:** Phlebotomy Hub (*Priority*)\n* **Due:** 2024-08-16 @ 09:00\n* **Status:** Open\n\n---\n\n### **3. NC-TASK-20240814-CLD-SCREEN**\n\n* **Title:** \u201cNon-invasive liver disease screen (MASLD, viral, autoimmune)\u201d\n* **Owner:** GP Practice (Liver Screening Queue)\n* **Due:** 2024-08-21\n* **Status:** Open\n\n---\n\n## **6. Safety & Governance Notes**\n\n* **Policy Applied:**\n\n  * NHS DMARD Safety Monitoring \u2013 \u201cStop MTX if ALT > 3\u00d7 ULN.\u201d\n  * Local Hepatotoxicity Protocol v5.2\n\n* **System Safety Comments:**\n\n  * \u201cHigh probability of MTX-related transaminitis; ensure follow-up imaging & screen.\u201d\n  * \u201cNo synthetic dysfunction (INR normal). No bilirubin rise. No acute liver failure features.\u201d\n\n* **Audit Trail (Extract):**\n\n  * 14:33 \u2013 Alert created\n  * 14:33 \u2013 Notifications dispatched\n  * 14:41 \u2013 Acknowledged (Hall_R)\n  * 14:42 \u2013 Action documented: MTX held\n\n---\n\n## **7. Impact on Medicines Dashboard**\n\n* MTX moved to \u201c**Withheld \u2013 Abnormal LFT**\u201d\n* Next review set: **2024-08-16 (await repeat LFTs)**\n* Risk Score updated \u2192 **High**\n",
        "dataSource": "Nervecentre"
    },
    "highlights": [
        {
            "text": "Rule 4.5 \u2013 ALT \u2265 3 \u00d7 ULN OR ALT \u2265 2 \u00d7 ULN in patients on hepatotoxic drugs (MTX).",
            "color": "red"
        },
        {
            "text": "ALT: 158 U/L (ULN 40 U/L \u2192 3.95 \u00d7 ULN)",
            "color": "red"
        },
        {
            "text": "AST: 132 U/L (H)",
            "color": "red"
        },
        {
            "text": "Alert Level: Level 3 \u2013 *Critical hepatotoxicity (MTX patient)*",
            "color": "red"
        },
        {
            "text": "MTX patient with ALT >3\u00d7 ULN \u2192 \u201cImmediate clinical review required\u201d",
            "color": "red"
        },
        {
            "text": "Methotrexate 15mg weekly (started ~12 weeks prior)",
            "color": "yellow"
        },
        {
            "text": "\u201cHigh probability of MTX-related transaminitis; ensure follow-up imaging & screen.\u201d",
            "color": "red"
        },
        {
            "text": "\u201cNo synthetic dysfunction (INR normal). No bilirubin rise. No acute liver failure features.\u201d",
            "color": "green"
        },
        {
            "text": "MTX moved to \u201cWithheld \u2013 Abnormal LFT\u201d",
            "color": "red"
        }
    ]
}